Key Points
- CFO Christine Mikail Cvijic sold 4,045 shares on March 13 at an average of $20.81 for a total of $84,176.45, reducing her stake by 3.68% to 105,798 shares (≈$2.20M); the transaction was disclosed on an SEC Form 4.
- Neurogene (NGNE) trades around $21.08 with a 52‑week range of $6.88–$37.27 and a market cap of $326.5M; analysts have a consensus "Moderate Buy" with a $44 price target amid mixed coverage (six Buys, one Hold, one Sell) and 52.4% institutional ownership.
Neurogene Inc. (NASDAQ:NGNE - Get Free Report) CFO Christine Mikail Cvijic sold 4,045 shares of the company's stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $20.81, for a total value of $84,176.45. Following the completion of the transaction, the chief financial officer directly owned 105,798 shares in the company, valued at approximately $2,201,656.38. The trade was a 3.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Neurogene Trading Down 2.3%
Neurogene stock opened at $21.08 on Wednesday. Neurogene Inc. has a 52 week low of $6.88 and a 52 week high of $37.27. The stock has a market cap of $326.53 million, a P/E ratio of -5.13 and a beta of 1.53. The stock has a 50 day moving average of $19.17 and a 200-day moving average of $21.65.
Hedge Funds Weigh In On Neurogene
A number of hedge funds have recently added to or reduced their stakes in NGNE. BNP Paribas Financial Markets increased its stake in Neurogene by 89.8% during the third quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company's stock valued at $36,000 after purchasing an additional 978 shares during the last quarter. PNC Financial Services Group Inc. lifted its position in shares of Neurogene by 43.6% in the 2nd quarter. PNC Financial Services Group Inc. now owns 4,055 shares of the company's stock worth $61,000 after buying an additional 1,232 shares during the last quarter. Daiwa Securities Group Inc. acquired a new position in shares of Neurogene in the 4th quarter valued at about $66,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Neurogene by 17.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company's stock valued at $82,000 after buying an additional 1,059 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Neurogene during the 4th quarter valued at about $165,000. Institutional investors and hedge funds own 52.37% of the company's stock.
Analysts Set New Price Targets
NGNE has been the subject of several recent analyst reports. Lifesci Capital assumed coverage on shares of Neurogene in a report on Monday, January 26th. They set an "outperform" rating and a $50.00 price objective for the company. Canaccord Genuity Group assumed coverage on shares of Neurogene in a research note on Friday, February 27th. They issued a "buy" rating on the stock. Wall Street Zen cut shares of Neurogene from a "hold" rating to a "sell" rating in a research report on Saturday, December 13th. HC Wainwright reiterated a "buy" rating and issued a $70.00 price target on shares of Neurogene in a research note on Tuesday, January 13th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Neurogene in a report on Thursday, January 22nd. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $44.00.
Check Out Our Latest Stock Analysis on Neurogene
About Neurogene
(
Get Free Report)
Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company's lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene's pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.
Neurogene's proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
